Based on technicals, not reality.
It's a guessing game, I see it like this...
If deals surface that indicate large volume production of chip/ip products, then it's about capturing market share so should be relooked at under a lens of total neuromorphic chip market potential i.e. $50B-$120B by 2026.
The company has stated multiple times that it anticipates saturating the market and as there are no other neuromorphic chip players and due diligence and product development timeframes are long we can fairly confidently consider "saturation" to be minimum 5% of potential market, so revenue of anywhere between $2.5-$6B
With a multiple of 4 times revenue we could be valued at up to $24B, making our SP of anywhere between $10-$15 approx.
DYOR
Chart, page-16021
-
-
- There are more pages in this discussion • 4,886 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $366.5M |
Open | High | Low | Value | Volume |
20.0¢ | 20.5¢ | 19.8¢ | $740.6K | 3.667M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
82 | 1395906 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 494804 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
80 | 1391793 | 0.195 |
62 | 1600034 | 0.190 |
31 | 1283131 | 0.185 |
52 | 1541743 | 0.180 |
17 | 632162 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 492796 | 16 |
0.205 | 917466 | 20 |
0.210 | 1596365 | 29 |
0.215 | 534039 | 23 |
0.220 | 758461 | 24 |
Last trade - 14.01pm 15/07/2024 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online